NCT05157087View on ClinicalTrials.gov

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

CompletedOBSERVATIONAL
Enrollment

16,246

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Asthma
Interventions
DRUG

Omalizumab

"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."

Trial Locations (1)

07936-1080

Novartis Investigational Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY